EUCTR2008-006872-31-IT进行中（未招募）不适用
A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy. - IMELDA
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Initial treatment phase: 1. Signed informed consent obtained prior to initiation of any study specific procedures or treatment as confirmation of the patients awareness and willingness to comply with the study requirements 2. Age ≥ 18 years 3. Patients with histologically confirmed and documented, HER2-negative metastatic adenocarcinoma of the breast, who are candidates for taxane-based chemotherapy 4. Documented ER/PgR status 5. ECOG PS of 0-1; 6. Life expectancy of ≥ 12 weeks
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous chemotherapy for mBC. Prior hormone therapy for metastatic disease is allowed. 2. Prior adjuvant/neoadjuvant chemotherapy within 6 m. prior to first study treatment administration. 3. Prior adjuvant/neoadjuvant anthracycline-based chemotherapy with a max. cumulative dose >360 mg/m2 for doxorubicin or >720 mg/m2 for epirubicin. 4. Prior radiotherapy for the treatment of metastatic disease. Radiotherapy administered for the relief of metastatic bone pain is allowed prior to study entry, as long as no more than 30% of marrow-bearing bone was irradiated. 5. Chronic daily treatment with aspirin (>325 mg/day) or clopidogrel (>75 mg/day). 6. Requirement for concurrent use of the antiviral agent sorivudine, or chemically related analogues, such as brivudine. 7. Chronic daily treatment with corticosteroids (dose of ≥10 mg/day methylprednisolone or equivalent), with the exception of inhaled steroids. 8. Current or recent treatment with another investigational drug or participation in another investigational study. 9. Inadequate bone marrow function: ANC: <1.5 x 10E9/l, platelet count <100 x 10E9/l or haemoglobin <8 g/dl. 10. Inadequate liver function, defined as: serum (total) bilirubin >1.5 x ULN for the institution AST/SGOT or ALT/SGPT >2.5 x ULN (>5 x ULN in patients with liver metastases) ALP >2.5 x ULN at baseline (>5 x ULN in patients with liver metastases, or >10 x ULN in patients with bone metastases). 11. Inadequate renal function, defined as: serum creatinine >1.5 x ULN creatinine clearance <50 ml/min (calculated according to Cockroft and Gault) urine dipstick for proteinuria >2+. Patients with ≥2+ proteinuria on dipstick analysis at baseline should undergo a 24-hour urine collection and must demonstrate ≤1g of protein in the 24-hour urine. 12. Patients not receiving anticoagulant medication who have an INR >1.5 or an aPTT >1.5 x ULN within 7 days prior to first study treatment. Note: Patients receiving full dose oral or parenteral anticoagulants may be included in the study as long as anticoagulant dosing has been stable for at least two weeks prior to study entry and the appropriate coagulation monitoring tests are within local therapeutic limits. 13. Evidence of spinal cord compression or brain metastases. 14. Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer. 15. Pregnant or lactating females. Serum pregnancy test to be assessed within 7 days prior to study treatment start, or within 14 days with a confirmatory urine pregnancy test within 7 days prior to study treatment start. 16. Women of childbearing potential (defined as <2 years after last menstruation and not surgically sterile) not using effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly). Et al.
研究者
相似试验
进行中（未招募）
1 期
A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy. - IMELDAHER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy.MedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2008-006872-31-FRF. Hoffmann-La Roche Ltd287
已完成
3 期
A clinical trial to study the effects of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during initial docetaxel plus bevacizumab therapyCTRI/2009/091/000423F HoffmannLa Roche360
进行中（未招募）
不适用
Phase II randomized study of intravenous bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine in patients with locally advanced or recurrent breast cancer with lymphangitic spread to the chest wall. - NDlocally advanced or recurrent breast cancer with lymphangitic spread to the chest wall.MedDRA version: 9.1Level: LLTClassification code 10006279Term: Breast neoplasmEUCTR2006-002152-16-ITISTITUTO EUROPEO DI ONCOLOGIA
尚未招募
3 期
A study to compare bevacizumab drug in low dose versus standard dose in lung cancer patientsCTRI/2023/06/054174Tata Memorial Hospital
进行中（未招募）
3 期
AMBITION studyBreast CancerJPRN-jRCT2031200335Yonemori Kan280